BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.86 -0.39%

-$0.03 today

Market cap
$149.27M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.37M

Average 0.37M

Returns on capital

BridgeBio Oncology Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-32.6%

avg 20391.6%

ROIC

-35.2%

avg -198566.7%

ROA

-29.9%

avg -3907.2%

Analysis

ROA is currently the strongest return metric at -29.9% versus its period average of -3907.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Yong Ben

Chief Medical & Development OfficerUSD 770.96K5243.53K0.05%

Pedro J. Beltran

Chief Executive Officer and DirectorUSD 767.66K55——

Frank McCormick

Co-Founder, Non-Executive Director & Chair of the Advisory BoardUSD 65K7631.68K0.04%

Neil Kumar

Executive ChairmanUSD 20K4731.68K0.04%

Aaron Chan

Vice President of Legal————

Bin Wang

Senior Vice President of Drug Discovery————

Rui Xu

Senior Vice President of Drug Discovery————

Daniel Watson

Senior Vice President of Chemistry, Manufacturing & Controls————

Idan Elmelech

Chief Operating Officer—3314.15K0.02%

Marc Cobo

VP of Finance & Controller—4513.81K0.02%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 21, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does BridgeBio Oncology Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BBOT's management, answered from reported figures.

Who manages BBOT?

BridgeBio Oncology Therapeutics Inc. (BBOT) lists 10 active executives. The top listed executive is Frank McCormick, Co-Founder, Non-Executive Director & Chair of the Advisory Board.

Are BBOT insiders buying or selling?

Recent insider activity shows net buying of $137.47M.